Show simple item record

dc.contributor.authorCatalá-López, F
dc.contributor.authorHutton, B
dc.contributor.authorDriver, JA
dc.contributor.authorPage, MJ
dc.contributor.authorRidao, M
dc.contributor.authorValderas, JM
dc.contributor.authorAlonso-Arroyo, A
dc.contributor.authorForés-Martos, J
dc.contributor.authorMartínez, S
dc.contributor.authorGènova-Maleras, R
dc.contributor.authorMacías-Saint-Gerons, D
dc.contributor.authorCrespo-Facorro, B
dc.contributor.authorVieta, E
dc.contributor.authorValencia, A
dc.contributor.authorTabarés-Seisdedos, R
dc.date.accessioned2018-05-14T15:27:30Z
dc.date.issued2017-04-04
dc.description.abstractBACKGROUND: The objective of this study will be to synthesize the epidemiological evidence and evaluate the validity of the associations between central nervous system disorders and the risk of developing or dying from cancer. METHODS/DESIGN: We will perform an umbrella review of systematic reviews and conduct updated meta-analyses of observational studies (cohort and case-control) investigating the association between central nervous system disorders and the risk of developing or dying from any cancer or specific types of cancer. Searches involving PubMed/MEDLINE, EMBASE, SCOPUS and Web of Science will be used to identify systematic reviews and meta-analyses of observational studies. In addition, online databases will be checked for observational studies published outside the time frames of previous reviews. Eligible central nervous system disorders will be Alzheimer's disease, anorexia nervosa, amyotrophic lateral sclerosis, autism spectrum disorders, bipolar disorder, depression, Down's syndrome, epilepsy, Huntington's disease, multiple sclerosis, Parkinson's disease and schizophrenia. The primary outcomes will be cancer incidence and cancer mortality in association with a central nervous system disorder. Secondary outcome measures will be site-specific cancer incidence and mortality, respectively. Two reviewers will independently screen references identified by the literature search, as well as potentially relevant full-text articles. Data will be abstracted, and study quality/risk of bias will be appraised by two reviewers independently. Conflicts at all levels of screening and abstraction will be resolved through discussion. Random-effects meta-analyses of primary observational studies will be conducted where appropriate. Parameters for exploring statistical heterogeneity are pre-specified. The World Cancer Research Fund (WCRF)/American Institute for Cancer Research (AICR) criteria and the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach will be used for determining the quality of evidence for cancer outcomes. DISCUSSION: Our study will establish the extent of the epidemiological evidence underlying the associations between central nervous system disorders and cancer and will provide a rigorous and updated synthesis of a range of important site-specific cancer outcomes. SYSTEMATIC REVIEW REGISTRATION: PROSPERO CRD42016052762.en_GB
dc.description.sponsorshipSpecific funding from the Generalitat Valenciana (PROMETEOII/2015/021) and CIBERSAM/Institute of Health Carlos III was received for this work. The funders were not involved in the design of the protocol or decision to submit the protocol for publication nor will they be involved in any aspect of the conduct of the review. BH is supported by a New Investigator Award from the Canadian Institutes of Health Research and the Drug Safety and Effectiveness Network. MJP is supported by an Australian National Health and Medical Research Council Early Career Fellowship (1088535). MR is partially funded by the Spanish Health Services Research on Chronic Patients Network (REDISSEC)/Institute of Health Carlos III. Ten_GB
dc.identifier.citationVol. 6: 69en_GB
dc.identifier.doi10.1186/s13643-017-0466-y
dc.identifier.urihttp://hdl.handle.net/10871/32851
dc.language.isoenen_GB
dc.publisherBioMed Centralen_GB
dc.relation.urlhttps://www.ncbi.nlm.nih.gov/pubmed/28376926en_GB
dc.rights© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.en_GB
dc.subjectAlzheimer’s diseaseen_GB
dc.subjectAmyotrophic lateral sclerosisen_GB
dc.subjectAnorexia nervosaen_GB
dc.subjectAutism spectrum disordersen_GB
dc.subjectBipolar disorderen_GB
dc.subjectCanceren_GB
dc.subjectCentral nervous system disorderen_GB
dc.subjectDepressionen_GB
dc.subjectDown’s syndromeen_GB
dc.subjectEpilepsyen_GB
dc.subjectHuntington’s diseaseen_GB
dc.subjectMeta-analysisen_GB
dc.subjectMultiple sclerosisen_GB
dc.subjectParkinson’s diseaseen_GB
dc.subjectSchizophreniaen_GB
dc.subjectSystematic reviewen_GB
dc.subjectCentral Nervous System Diseasesen_GB
dc.subjectHumansen_GB
dc.subjectIncidenceen_GB
dc.subjectMeta-Analysis as Topicen_GB
dc.subjectNeoplasmsen_GB
dc.subjectObservational Studies as Topicen_GB
dc.subjectResearch Designen_GB
dc.subjectReview Literature as Topicen_GB
dc.titleCancer and central nervous system disorders: protocol for an umbrella review of systematic reviews and updated meta-analyses of observational studies.en_GB
dc.typeArticleen_GB
dc.date.available2018-05-14T15:27:30Z
exeter.place-of-publicationEnglanden_GB
dc.descriptionThis is the final version of the article. Available from the publisher via the DOI in this record.en_GB
dc.identifier.eissn2046-4053
dc.identifier.journalSystematic Reviewsen_GB


Files in this item

This item appears in the following Collection(s)

Show simple item record